DE60027700D1 - Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden - Google Patents

Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden

Info

Publication number
DE60027700D1
DE60027700D1 DE60027700T DE60027700T DE60027700D1 DE 60027700 D1 DE60027700 D1 DE 60027700D1 DE 60027700 T DE60027700 T DE 60027700T DE 60027700 T DE60027700 T DE 60027700T DE 60027700 D1 DE60027700 D1 DE 60027700D1
Authority
DE
Germany
Prior art keywords
optionally substituted
compounds
receptor ligands
integrin receptor
bicyclic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60027700T
Other languages
English (en)
Other versions
DE60027700T2 (de
Inventor
Edward Clark
Robert Eastwood
Victor Harris
Clive Mccarthy
David Morley
Dennis Pickett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9903532.1A external-priority patent/GB9903532D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of DE60027700D1 publication Critical patent/DE60027700D1/de
Publication of DE60027700T2 publication Critical patent/DE60027700T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
DE60027700T 1999-02-16 2000-02-16 Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden Expired - Fee Related DE60027700T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9903532 1999-02-16
GBGB9903532.1A GB9903532D0 (en) 1999-02-16 1999-02-16 Chemical compounds
US14144599P 1999-06-29 1999-06-29
US141445P 1999-06-29
PCT/GB2000/000553 WO2000049005A1 (en) 1999-02-16 2000-02-16 Bicyclic compounds and their use as integrin receptor ligands

Publications (2)

Publication Number Publication Date
DE60027700D1 true DE60027700D1 (de) 2006-06-08
DE60027700T2 DE60027700T2 (de) 2007-05-03

Family

ID=26315145

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60027700T Expired - Fee Related DE60027700T2 (de) 1999-02-16 2000-02-16 Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden

Country Status (11)

Country Link
US (1) US6593354B2 (de)
EP (1) EP1153017B1 (de)
JP (1) JP2002537292A (de)
AT (1) ATE325105T1 (de)
AU (1) AU775208B2 (de)
CA (1) CA2362862A1 (de)
DE (1) DE60027700T2 (de)
DK (1) DK1153017T3 (de)
ES (1) ES2263447T3 (de)
PT (1) PT1153017E (de)
WO (1) WO2000049005A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
BR0010599A (pt) * 1999-04-12 2002-02-13 Aventis Pharma Ltd Compostos de heteroarila bicìclicos substituìdos como antagonistas de integrina
GB0001346D0 (en) * 2000-01-21 2000-03-08 Astrazeneca Uk Ltd Chemical compounds
GB0004686D0 (en) * 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
ATE524441T1 (de) 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
ES2382806T3 (es) 2003-07-24 2012-06-13 Daiichi Sankyo Company, Limited Compuesto ácido ciclohexanocarboxílico
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
BRPI0508098A (pt) * 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
DE102006021878A1 (de) * 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8674113B2 (en) 2010-12-10 2014-03-18 Boehringer Ingelheim International Gmbh Compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025637A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
US4100168A (en) 1974-09-20 1978-07-11 Lilly Industries Ltd. 2,5 OR 2,6-Disubstituted benzoxazoles
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
ATE204857T1 (de) * 1996-03-29 2001-09-15 Searle & Co Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
JPH10330369A (ja) 1997-04-04 1998-12-15 Sumitomo Pharmaceut Co Ltd 複素環化合物
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
WO2000005223A2 (en) * 1998-07-23 2000-02-03 Astrazeneca Ab Heterocyclic derivatives and their use as integrin inhibitors
GB9916374D0 (en) * 1998-07-23 1999-09-15 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1153017B1 (de) 2006-05-03
ATE325105T1 (de) 2006-06-15
DK1153017T3 (da) 2006-07-17
CA2362862A1 (en) 2000-08-24
DE60027700T2 (de) 2007-05-03
JP2002537292A (ja) 2002-11-05
EP1153017A1 (de) 2001-11-14
WO2000049005A1 (en) 2000-08-24
PT1153017E (pt) 2006-07-31
AU775208B2 (en) 2004-07-22
ES2263447T3 (es) 2006-12-16
US6593354B2 (en) 2003-07-15
US20020137782A1 (en) 2002-09-26
AU2561700A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
DE60027700D1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
ATE325796T1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
YU41299A (sh) Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista
TW200635904A (en) Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
TNSN06203A1 (en) Derivatives of n- (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
CA2286723A1 (en) Tricyclic compounds
DE602005007064D1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
SG160195A1 (en) N-phenyl-2-pyrimidine-amine derivatives
ATE286896T1 (de) Substituierte bicyclische heteroaryl-verbindungen als integrin antagonisten
TW200745034A (en) New compounds
DE60318030D1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
TR200101155T2 (tr) 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III
AU2003254852A8 (en) Fused heterocyclic compounds as peptidase inhibitors
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
GB0323204D0 (en) Organic compounds
WO2008111632A1 (ja) ２，２，４－トリメチル－６－フェニル－１，２－ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
DE60327922D1 (de) Harnstoff-linker verbindungen und ihre verwendung als ppar regulatoren
EP1189900A4 (de) Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe
RS20060290A (en) Tetrazole derivatives and methods of treatment of metabolic- related disorders thereof
HUP0200121A2 (hu) Kalcilitikus vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203187A2 (hu) Izoxazolszármazékok mint foszfodiészteráz VII inhibitorok és ezeket tartalmazó gyógyszerkészítmények
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
YU39503A (sh) Derivati pirimidina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee